# Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

> **NCT03439124** · PHASE3 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 138 (actual)

## Conditions studied

- Community-acquired Pneumonia (CAP)
- Hospital-acquired Pneumonia (HAP)

## Interventions

- **DRUG:** ceftobiprole medocaril
- **DRUG:** IV standard-of-care cephalosporin

## Key facts

- **NCT ID:** NCT03439124
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-03-16
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03439124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03439124, "Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03439124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*